Evidence-based Pharmacy Practice (EBPP):

Attention deficit hyperactivity disorder (ADHD)

Angelene van der Westhuizen BPharm, MSc (Pharmacology)
Department of Pharmacology, University of Pretoria

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is one of the most common childhood psychiatric conditions. The core symptoms of ADHD are hyperactivity, impulsivity and/or inattention. These symptoms can lead to problems in academic achievement, behavior, personal relationships with family and peers and low self-esteem. Symptoms first present in childhood and can continue through adolescence into adulthood. Co-morbid disorders include oppositional defiant disorder, conduct disorder, anxiety, depression, tics and Tourette’s syndrome, and epilepsy. Stimulants are first-line in the pharmacological treatment of ADHD. Methylphenidate is the most common drug prescribed in this condition. Pharmacological treatment should form part of a comprehensive treatment plan which should include psychological, educational and social measures assessed on an individual basis.

Definitions

ADD stands for Attention Deficit Disorder and ADHD stands for Attention Deficit Hyperactivity Disorder. Internationally ADHD is the term that includes both ADD and ADHD.

ADHD is a behavioral syndrome characterized by the core symptoms of inattention, hyperactivity and impulsivity. ADHD can be diagnosed using either DSM-IV or ICD-10 criteria.

DSM-IV – Diagnostic and Statistical Manual of Mental Disorders 4th Edition. Under this classification ADHD is divided into three types namely: predominantly inattentive, predominantly hyperactive-impulsive or a combination of the two.

ICD-10 – International Classification of Mental and Behavioural Disorders 10th revision. Under this classification the signs of ADHD are given the name “Hyperkinetic disorder”.

Epidemiology

ADHD is a common disorder which affects 4% to 5% of South African children. ADHD is more common in boys than girls (male to female ratio 4:1 for predominantly hyperactive type and 2:1 for predominantly inattentive type). Girls display more inattention and less hyperactive and impulsive symptomology.

Children and adolescents with ADHD frequently have co-morbid psychiatric disorders. These can be oppositional disorder, conduct disorder, depression, anxiety disorder, and with many developmental disorders such as speech and language delays and learning disabilities. The co-morbid conditions can be primary or secondary (exacerbated by the ADHD). Other conditions such as tics and Tourette’s syndrome and epilepsy can also co-exist with ADHD. ADHD was thought to resolve around puberty as most hyperactive children become less hyperactive around this time. The symptoms of inattention and impulsiveness, however, can persist into adulthood. Recent studies have shown that 30% to 70% of children experience problems related to ADHD in adulthood. It is estimated that 4% of the adult population in South Africa has ADHD. While ADHD is more common in boys in children and adolescents, adult ADHD occurs equally in men and women. The prevalence of ADHD appears to decrease with age. An overlap of characteristics and symptoms with other psychopathological conditions can often lead to underdiagnosis or non-treatment of ADHD in adults. There are currently no officially recognized adult ADHD diagnostic criteria but the DSM-V (due in May 2013) is expected to include criteria for adult ADHD. Other conditions that may look like ADHD include some medical causes of tiredness (anaemia, hypothyroidism) and the more severe anxiety and mood disorders. If an adult has ADHD they will have always had ADHD. Those affected are likely to develop coping mechanisms as they mature which helps them to compensate for some or all their impairments.
Aetiology/Pathophysiology
A specific cause of ADHD is not known. Genetic components as well as developmental and psychosocial factors are implicated in the pathophysiology of ADHD. There is strong evidence for a genetic basis to ADHD. The child of a parent with ADHD has up to a 50% chance of developing ADHD. Monozygotic twins have up to a 92% concordance rate for ADHD and dizygotic twins 33%. A number of genes have been identified to play a role in the development of ADHD. Psychosocial factors such as being institutionalised, prolonged emotional deprivation and adverse parent child relationships have also been implicated in the development of ADHD. Prenatal exposure to tobacco is associated with the development of ADHD. Other factors that have been associated with ADHD but are inconsistent include: prematurity and low birth weight, prenatal exposure to alcohol and head trauma in young children. Diet has also been suggested to play a secondary role in the pathogenesis of ADHD but the significance is controversial.

Diagnosis
The diagnosis of ADHD is clinical and based on comprehensive medical, developmental, educational and psychological evaluations. In North America, the DSM-IV criteria are used as a basis for diagnosis while countries in Europe usually use the ICD-10. In South Africa, the DSM-IV is most commonly used. If the DSM-IV criteria are used rather than ICD-10, a diagnosis of ADHD is three to four times more likely. ADHD-specific behaviour scales can be used to gather information from parents and teachers regarding behaviour. These scales are not recommended to be used in isolation to diagnose ADHD but can definitely aid in the diagnosis.

Differential diagnosis
Other conditions which may have similar symptoms to ADHD include:

• Allergies/Asthma – difficulty with breathing can interrupt a child’s concentration.
• Diabetes/hypoglycaemia – can have an affect on concentration and energy levels.
• Hearing or visual problems – can lead to behaviour outbursts, incompletion of work and disturbance of classmates and hyperactivity.
• Lead intoxication – can lead to hyperactivity.
• Learning difficulties – can lead to frustration and ADHD-like behaviour.
• Emotional difficulties: could be due to divorce, bereavement, or a traumatic event which may lead to hyperactivity.

Clinical approaches to ADHD for the pharmacist
Pharmacists can play an important role in ADHD by creating an awareness of the condition by educating patients and carers and referring when necessary and also by giving advice on how best to take medications. The pharmacist can explain the importance of not chewing, crushing or dividing extended release preparations and can give advice on how to make it easier to administer these preparations. The following aids can be suggested to aid swallowing:

• Take a couple of swallows of milk or juice before taking the capsule, to make the throat and tongue more slippery.
• Try swallowing the capsule with a teaspoon of soft food, e.g. yoghurt or mousse.
• Try putting the capsule on the back of the tongue, taking a sip of a favourite drink and tilting the head back before swallowing.

Pharmacists can also advise on how to manage side effects associated with stimulant use (Refer to Table II). They can also educate patients and their families about the possible adverse effects of atomoxetine especially the warning signs of hepatotoxicity (such as abdominal pain, unexplained nausea, malaise, and darkening of the urine or jaundice) and suicidal ideation. Pharmacists can also help to improve treatment adherence in patients with ADHD by:

• Recommending the use of simple drug regimens (e.g. once-daily modified-release doses).
• Offering clear instructions (pictures or written) about how to take the drug.
• Advising patients and carers: providing reminders to take medication regularly (e.g. alarms, clocks, pill boxes or notes on calenders or fridges); helping to incorporate medication into daily routines; and helping them develop a positive attitude about taking medication, including praise and positive reinforcement.

Pharmacists can also refer teenagers, adults and parents of children who have ADHD to information and support services such as ADHDSA (www.adhdsupport.co.za).

Available treatment options
Non pharmacological management

• Behaviour therapy
• Psychological therapy
• Complementary and alternative medicines (CAMs)
• Dietary modifications

Pharmacological treatment

• Stimulants
• Non-stimulants
• Other medications e.g. antidepressants, clonidine, antipsychotics

Therapeutic objectives
The aims of treating ADHD include both remission of symptoms and normalisation of functioning, including school (and work performance) and social interactions. Desired results include:

• Improvements in relationships with parents, siblings, teachers and peers.
• Decreased disruptive behaviours.
• Improved academic performance, particularly in volume of work, efficiency, completion and accuracy.
• Increased independence in self-care or homework.
• Improved self-esteem.
• Enhance safety in the community e.g. such as crossing the road and riding bicycles.
Table I: Diagnostic criteria for ADHD, DSM-IV-TR

Attention-deficit/hyperactivity disorder

A. Either (1) or (2)

(1) Six or more of the following symptoms of inattention have persisted for at least six months to a degree that is maladaptive and inconsistent with developmental level:

Inattention:
- Often fails to give close attention to detail or makes careless mistakes in schoolwork, work, or other activities
- Often has difficulty sustaining attention in tasks or play activities
- Often does not seem to listen when spoken to directly
- Often does not follow through on instructions and fails to finish schoolwork, chores, or duties in the workplace (not due to oppositional behaviour or failure to understand instructions)
- Often has difficulty organising tasks and activities
- Often avoids, dislikes, or is reluctant to engage in tasks that require sustained mental effort (such as schoolwork or homework)
- Often loses things necessary for tasks or activities (e.g. toys, school assignments, pencils, books or tools)
- Is often easily distracted by extraneous stimuli
- Is often forgetful in daily activities

(2) Six (or more) of the following symptoms of hyperactivity-impulsivity have persisted for at least six months to a degree that is maladaptive and inconsistent with developmental level:

Hyperactivity:
- Often fidgets with hands or feet or squirms in seat
- Often leaves seat in classroom or in other situations where remaining in seat is expected
- Often runs about or climbs excessively in situations in which it is inappropriate (in adolescents or adults, may be limited to subjective feelings of restlessness)
- Often has difficulty playing or engaging in leisure activities quietly
- Is often ‘on the go’ or often acts as if ‘driven by a motor’
- Often talks excessively

Impulsivity:
- Often blurts out answers before questions have been completed
- Often has difficulty awaiting turn
- Often interrupts or intrudes on others (e.g. butts into conversations or games)

B. Some hyperactive-impulsive or inattentive symptoms that caused impairment were present before seven years of age

C. Some impairment from the symptoms is present in two or more settings (e.g. at school [or work] and at home)

D. There must be clear evidence of clinically significant impairment that affects social, academic, or occupational functioning

E. The symptoms do not occur exclusively during the course of a pervasive developmental disorder, schizophrenia, or other psychotic disorder and are not better accounted for by another mental disorder (e.g. mood disorder, anxiety disorder, dissociative disorder or a personality disorder)

Code based on type

- ADHD combined type
  Both criteria A1 and A2 are met for the past 6 months

- ADHD predominantly inattentive type
  Criterion A1 is met, but criterion A2 is not met for the past 6 months

- ADHD predominantly hyperactive-impulsive type
  Criterion A2 is met but criterion A1 is not met for the past 6 months
Targeted outcomes need to be developed on an individual basis for each patient and they require input from the children themselves as well and parents and teachers.18

**Non pharmacological management**

**Behaviour therapy**

Behaviour therapy includes a broad range of interventions that have a common goal of modifying the physical and social environment to alter or change behaviour.18 It has not been demonstrated to significantly reduce the core symptoms of ADHD but it can improve behaviour problems often seen in children with ADHD.18 It may be recommended as an initial treatment if ADHD symptoms are mild with minimal impairment, diagnosis is uncertain, parents reject medication treatment or there is marked disagreement concerning the diagnosis between parents or parents and teachers.1

Behaviour therapy is usually implemented by training parents and teachers in specific techniques of improving behaviour.19 Parents can help support better behaviour in a child with ADHD by19:

- Maintaining a daily schedule.
- Keeping distractions to a minimum.
- Providing specific and logical places for the child to keep his schoolwork, toys, and clothes.
- Setting small, reachable goals.
- Rewarding positive behaviour.
- Using charts and checklists to help the child stay “on task”.
- Limiting choices.
- Finding activities in which the child can be successful (e.g. hobbies and sports)
- Using calm discipline (e.g. time out, distraction, removing the child from the situation)

Other effective behavioural techniques recommended by the American Academy of Pediatrics are included in Table III.

**Psychological therapy**

Psychological interventions designed to change the child’s emotional status (e.g. play therapy) or thought patterns (e.g. cognitive behaviour therapy) have little documented efficacy in the treatment of children with ADHD.18 Gains achieved in the treatment setting are not usually transferred into the classroom or home.18

**CAMs**

There are many CAMs that are promoted for ADHD but their use is controversial. Consumers of these therapies are often not knowledgeable about their usefulness and effectiveness.20 The most often used of these therapies are dietary modifications, dietary supplements, herbal treatments, biofeedback, sound therapy, exercise and chiropractice.20 In a study conducted in the Eastern Cape in which a questionnaire survey was conducted, it was seen that natural products such as Eye q®, Biostrath®, and evening primrose oil had been used most often, followed by diet modifications.20 Other alternative treatments used included occupational therapy, the playing of more sport,
physiotherapy, speech therapy and remedial therapy.\textsuperscript{29} It was found in this study that symptom control was insufficient when pharmacological treatment for ADHD was stopped and only non-pharmacological treatments were used.\textsuperscript{29} It was recommended that if alternative therapies were to be used in ADHD they should be combined with pharmacological treatment.\textsuperscript{29}

**Dietary modifications**

The influence of diet on attention, hyperactivity and behaviour is controversial.\textsuperscript{7} The following areas of diet have been implicated:\textsuperscript{7,16}:

- Food additives (artificial colours and flavours, preservatives)
- Refined sugar intake (may be due to allergy or a functional reactive hypoglycaemia which triggers stress hormones like adrenaline)
- Fruits and vegetables containing high levels of salicylates
- Food sensitivity (allergy and intolerance)
- Essential fatty acid deficiency
- Iron and zinc deficiency

These areas of diet generally do not impact to a clinically significant level on ADHD and do not account for the majority of cases of ADHD.\textsuperscript{7} However, there is a small subset of children who may demonstrate mild adverse behavioural effects in response to certain dietary influences.\textsuperscript{7} Major practice guidelines for the treatment of ADHD do not routinely recommend elimination of food additives in the management of children with ADHD.\textsuperscript{3,7,18}

**Pharmacological treatment**

Pharmacological treatment aims to increase the amount of dopamine or noradrenaline available.\textsuperscript{8} Only methylphenidate and atomoxetine are licensed for use in ADHD in South Africa. (Refer to Table IV.) It seems to be established that pharmacological treatment is more effective than behavioural treatment alone.\textsuperscript{1}

When choosing a drug prescribers should consider:\textsuperscript{10}:

- Co-morbidities e.g. tics (can be worsened by methylphenidate), Tourette’s syndrome, epilepsy.
- Side effects.
- Potential for drug misuse (can change with circumstances and age e.g. going into puberty).
- Preferences of patients and carers (e.g. extended release preparations so no medication needs to be taken at school).

Treatment should be continued for as long as it is effective.\textsuperscript{3} Treatment should be reviewed at least annually in children and adolescents and annually in adults.\textsuperscript{3} The following points should be covered in the review:\textsuperscript{5}:

- Clinical need, benefits and side effects of treatment.
- The views of the person with ADHD as well as the parents, carers and teachers, or spouse close friend in adults.
- The effect of missed doses, planned dose reductions and brief periods of no treatment.
- The preferred pattern of drug use (with or without periods without treatment e.g. weekdays only).

- Any coexisting conditions which should be treated or referred if necessary.
- The need for psychological, social and occupational support for the person and their parents.

Dosing schedules of methylphenidate can be adjusted to cover specific days and times e.g. during school hours and while doing homework especially in patients who suffer from the predominantly inattentive type of ADHD.\textsuperscript{2,18} Drug holidays are not routinely recommended according to the NICE guidelines.\textsuperscript{3} If they are to be employed, consideration must be given to the risks of negative effects on learning, socialisation and self-image while off therapy when determining the frequency and duration of drug holidays.\textsuperscript{8} Drug holidays can be tried on weekends or holidays and placebo periods may also be tried for five to 10 school days to ensure reliability of observations to determine whether the drugs are still needed.\textsuperscript{2} Drug holidays are not an option for patients taking atomoxetine as it needs to be taken on a continual basis.\textsuperscript{22}

**Monitoring**

Careful documentation of baseline symptoms and complaints over a one month pre-drug period is beneficial in being able to assess therapeutic and adverse outcomes.\textsuperscript{8} Depending on which medication a patient is taking, side effects need to be monitored. Routine blood tests and ECGs are not recommended unless there is a clinical indication.\textsuperscript{3} The child's height, weight, blood pressure and pulse should be monitored for patients taking either methylphenidate or atomoxetine.\textsuperscript{3,22} Any occurrence of seizures would result in termination of therapy.\textsuperscript{3} In patients taking methylphenidate, the occurrence of tics, psychotic symptoms such as delusions or hallucinations, anxiety symptoms and drug misuse and diversion need to be monitored and if they occur acted upon.\textsuperscript{7} In patients taking atomoxetine side effects concerning the reproductive system and sexual function need to be monitored and the warning signs of hepatotoxicity and agitation, irritability and suicidal thinking and self-harm need to be identified and treatment terminated if necessary.\textsuperscript{3} Routine liver function tests are not necessary so long as patients and carers are warned of the rare potential for liver damage and the warning signs.\textsuperscript{3}

**Stimulants**

- Methylphenidate

Methylphenidate blocks the dopamine transporter thus reducing dopamine reuptake and increasing dopamine in synapses.\textsuperscript{10} The dose needs to be titrated over four weeks with weekly increments.\textsuperscript{10} Dosing should be titrated for maximum individual efficacy and minimum side effects.\textsuperscript{8} The appropriate dose is determined by the age and weight of the patient but the desired outcomes such as improved academic functioning and better behaviour also have an influence on the optimal dose.\textsuperscript{10} Learning is often enhanced at low doses but improvement in behaviour often requires larger doses.\textsuperscript{9} Methylphenidate only alleviates symptoms while each dose is active.\textsuperscript{10} Methylphenidate is available in immediate and modified release forms.\textsuperscript{10} The immediate release product takes effect an hour after adminis-
### Table IV: Pharmacological preparations indicated for ADHD in South Africa

<table>
<thead>
<tr>
<th>Drug</th>
<th>Brand*</th>
<th>Strength</th>
<th>Dosage instructions</th>
<th>Additional information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methylphenidate HCl</td>
<td>Concerta® ER tablets</td>
<td>18 mg</td>
<td><strong>New patients</strong> 18 mg once daily. Adjust in 18 mg increments at weekly intervals to max 54 mg/d for children 6–12 yrs. 72 mg/d for adolescents 13–18 yrs.</td>
<td>Not for children under 6 years. Administer once in daily in the mornings. Effects shown to be present 12 hours after dose. Swallow whole and never crush, chew or divide. Non-absorbable tablet shell may be seen in stool. Longer acting stimulants offer greater convenience, confidentiality, and adherence with single daily dosing but may have greater problematic effects on evening appetite and sleep.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>36 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>54 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methylphenidate HCl</td>
<td>Methyphenidate HCI-Douglas</td>
<td>10 mg</td>
<td>Initially 5 mg before breakfast and 5 mg before lunch with gradual weekly increments of 5–10 mg to max 60 mg/d. Admin to a total daily dose in divided doses. Dose in terms of body wt: usual 0.25 mg/kg/d, double each week to 2 mg/kg. Consider short-act trial dose at bedtime if rebound effects experienced.</td>
<td>Short-acting stimulants often used as initial treatment in small children (&lt; 16 kg) but have disadvantage of bd-tds dosing to control symptoms throughout the day.</td>
</tr>
<tr>
<td>Methylphenidate HCl</td>
<td>Ritalin® tablets</td>
<td>10 mg</td>
<td>Initiate in small doses with gradual weekly increments. Daily dose over 60 mg not recommended. Discontinue if no improvement observed after appropriate dose adjustment over one month.</td>
<td>Short-acting stimulants often used as initial treatment in small children (&lt; 16 kg) but have disadvantage of bd-tds dosing to control symptoms throughout the day.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>20 mg</td>
<td>Recommended start dose 20 mg. Dose to replace standard formula: 20 mg LA od to replace 10 mg bd. 30 mg LA od to replace 15 mg bd. 40 mg od to replace 20 mg bd. In case of other regimens use clinical judgement.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>30 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>40 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methylphenidate HCl</td>
<td>Ritalin® LA capsules</td>
<td>20 mg</td>
<td>Recommended start dose 20 mg. Dose to replace standard formula: 20 mg LA od to replace 10 mg bd. 30 mg LA od to replace 15 mg bd. 40 mg od to replace 20 mg bd. In case of other regimens use clinical judgement.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atomoxetine HCl</td>
<td>Straterra® capsules</td>
<td>10 mg</td>
<td><strong>Child and adolescent &lt; 70 kg:</strong> Initial total daily dose 0.5 mg/kg. Maintenance dose: initial dose for 7 days before upward titration according to clinical response. Recommended maintenance dose: 1.2 mg/kg/day. No add benefits seen with higher dose.</td>
<td>If dose missed take ASAP but prescribed total daily dose not to be exceeded in any 24 hours. Consider if active substance abuse or severe side effects of stimulants (mood lability or tics) give every morning or bd (effects on late evening behaviour). Monitor closely for suicidal thinking or behaviour, clinical worsening, or unusual changes in behaviour.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>18 mg</td>
<td><strong>Child and adolescent &gt; 70 kg:</strong> Initial total daily dose 40 mg. Maintenance dose: initial dose for 7 days before upward titration according to clinical response. Recommended maintenance dose: 80 mg. No additional benefits seen with higher dose.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>25 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>40 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>60 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Drug</th>
<th>Brand*</th>
<th>Strength</th>
<th>Dosage instructions</th>
<th>Additional information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methylphenidate HCl</td>
<td>Concerta® ER tablets</td>
<td>18 mg</td>
<td><strong>New patients</strong> 18 mg once daily. Adjust in 18 mg increments at weekly intervals to max 54 mg/d for children 6–12 yrs. 72 mg/d for adolescents 13–18 yrs.</td>
<td>Not for children under 6 years. Administer once in daily in the mornings. Effects shown to be present 12 hours after dose. Swallow whole and never crush, chew or divide. Non-absorbable tablet shell may be seen in stool. Longer acting stimulants offer greater convenience, confidentiality, and adherence with single daily dosing but may have greater problematic effects on evening appetite and sleep.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>36 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>54 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methylphenidate HCl</td>
<td>Methyphenidate HCI-Douglas</td>
<td>10 mg</td>
<td>Initially 5 mg before breakfast and 5 mg before lunch with gradual weekly increments of 5–10 mg to max 60 mg/d. Admin to a total daily dose in divided doses. Dose in terms of body wt: usual 0.25 mg/kg/d, double each week to 2 mg/kg. Consider short-act trial dose at bedtime if rebound effects experienced.</td>
<td>Short-acting stimulants often used as initial treatment in small children (&lt; 16 kg) but have disadvantage of bd-tds dosing to control symptoms throughout the day.</td>
</tr>
<tr>
<td>Methylphenidate HCl</td>
<td>Ritalin® tablets</td>
<td>10 mg</td>
<td>Initiate in small doses with gradual weekly increments. Daily dose over 60 mg not recommended. Discontinue if no improvement observed after appropriate dose adjustment over one month.</td>
<td>Short-acting stimulants often used as initial treatment in small children (&lt; 16 kg) but have disadvantage of bd-tds dosing to control symptoms throughout the day.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>20 mg</td>
<td>Recommended start dose 20 mg. Dose to replace standard formula: 20 mg LA od to replace 10 mg bd. 30 mg LA od to replace 15 mg bd. 40 mg od to replace 20 mg bd. In case of other regimens use clinical judgement.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>30 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>40 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methylphenidate HCl</td>
<td>Ritalin® LA capsules</td>
<td>20 mg</td>
<td>Recommended start dose 20 mg. Dose to replace standard formula: 20 mg LA od to replace 10 mg bd. 30 mg LA od to replace 15 mg bd. 40 mg od to replace 20 mg bd. In case of other regimens use clinical judgement.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atomoxetine HCl</td>
<td>Straterra® capsules</td>
<td>10 mg</td>
<td><strong>Child and adolescent &lt; 70 kg:</strong> Initial total daily dose 0.5 mg/kg. Maintenance dose: initial dose for 7 days before upward titration according to clinical response. Recommended maintenance dose: 1.2 mg/kg/day. No add benefits seen with higher dose.</td>
<td>If dose missed take ASAP but prescribed total daily dose not to be exceeded in any 24 hours. Consider if active substance abuse or severe side effects of stimulants (mood lability or tics) give every morning or bd (effects on late evening behaviour). Monitor closely for suicidal thinking or behaviour, clinical worsening, or unusual changes in behaviour.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>18 mg</td>
<td><strong>Child and adolescent &gt; 70 kg:</strong> Initial total daily dose 40 mg. Maintenance dose: initial dose for 7 days before upward titration according to clinical response. Recommended maintenance dose: 80 mg. No additional benefits seen with higher dose.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>25 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>40 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>60 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Insomnia and headache.** Less common side effects include tics and emotional lability/irritability. Strategies for dealing with side effects include monitoring, dose adjustment and adjunctive pharmacotherapy to treat the side effects. Refer to Table II for the management of side effects of stimulants.

Other stimulants such as dextroamphetamine and mixed amphetamine salts (Adderall®) are not available in South Africa.

**Non-stimulants**

- **Atomoxetine**
  Atomoxetine (Strattera®) is a noradrenaline reuptake inhibitor. Atomoxetine can be dosed once or twice daily with the second...
dose given in the evening.\textsuperscript{1,17} Atomoxetine may have less pronounced effects on appetite and sleep than methylphenidate but may produce relatively more nausea or sedation.\textsuperscript{1} Peak efficacy occurs between two to six weeks after initiation but can take up to eight weeks which is in contrast to the stimulants, which give a rapid response.\textsuperscript{11} Side effects include constipation, dry mouth, nausea, decreased appetite, dizziness, insomnia, sexual side effects, menstrual cramps and difficulty in passing urine.\textsuperscript{23} Gastric side effects may be reduced by taking with food.\textsuperscript{10} It can also cause hepatotoxicity and increase the risk of suicidal ideation.\textsuperscript{23} It should not be taken in patients with glaucoma or in patients who have received a monoamine oxidase inhibitor in the past fourteen days.\textsuperscript{23} It has also shown to be effective in co-morbid anxiety and it is a good alternative to methylphenidate (which has the potential for abuse and diversion) in adolescents and adults with a substance abuse disorder.\textsuperscript{17} Atomoxetine has not been found to be effective for the treatment of co-morbid depression.\textsuperscript{17} It does not worsen tics in patients with ADHD and concomitant Tourette’s syndrome.\textsuperscript{23}

Other medications

Other medications may be effective in reducing the symptoms of ADHD although data from controlled studies is limited.\textsuperscript{22} These medications are usually tried when patients respond poorly to a trial of methylphenidate or atomoxetine, or have unacceptable side effects, or have significant co-morbid conditions that warrant their use.\textsuperscript{22} (Refer to Table V)

- **Antidepressants**

Antidepressants that have been used in the treatment of ADHD include tricyclic antidepressants (TCAs), such as imipramine, desipramine and nortriptyline and dopamine reuptake inhibitors such as bupropion.\textsuperscript{22}

Tricyclic antidepressants (TCAs) inhibit the reuptake of noradrenaline and serotonin.\textsuperscript{22} They are considered to be second-line after stimulants and atomoxetine.\textsuperscript{22} TCAs have been associated with cardiovascular adverse events so a review of the patient’s history and family history is essential before initiating therapy.\textsuperscript{22} They also have anticholinergic side effects such as dry mouth and constipation which may limit their use and they also lower the seizure threshold.\textsuperscript{22} Desipramine should be used with extreme caution in children and adolescents (if at all) because there have been reports of sudden death.\textsuperscript{1}

### Table V: Other agents used for ADHD and associated symptoms\textsuperscript{8,17}

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosing</th>
<th>Adverse effects</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bupropion</td>
<td>50–300 mg/d; 3 mg/kg/d by end of week one may increase to 6 mg/kg/d or max of 300 mg/d as tolerated</td>
<td>Nausea, insomnia, rash, tics, dose-related risk of seizures.</td>
<td>Lowers seizure threshold; contraindicated if current seizure disorder. Usually given in divided doses bd for children and tds for adolescents for both safety and effectiveness.</td>
</tr>
<tr>
<td>Imipramine</td>
<td>1–4 mg/kg/d with a maximum of 200 mg/d</td>
<td>Sedation, dizziness, constipation, heart block, weight gain, overdose toxicity, rapid heartbeat.</td>
<td>Obtain baseline ECG before starting.</td>
</tr>
<tr>
<td>Desipramine</td>
<td>0.5–1 mg/kg/d increase as tolerated to 2–3 mg/kg/d maximum of 300 mg/day (adults only)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nortriptyline</td>
<td>0.5–2 mg/kg/d with a maximum of 100 mg/d</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clonidine</td>
<td>&lt; 45 kg 0.05 mg at bedtime; titrate in 0.05 mg increments bd, tds, qds &gt; 45 kg 0.1 mg at bedtime; titrate in 0.1 mg increments bd, tds, qds Max dose 27–40.5 kg/0.2 mg; 40.5–45 kg/0.3 mg; &gt; 45 kg: 0.4mg</td>
<td>Sedation, dizziness, heart block, constipation.</td>
<td>May be used alone or as adjuvant to another med for ADHD. Effective for impulsivity and hyperactivity; modulating mood level; tics worsening from stimulants; sleep disturbances.</td>
</tr>
<tr>
<td>Risperidone</td>
<td>0.25–0.5 mg bd may titrate every 3–4 days as tolerated to response (1–4 mg/d)</td>
<td>Extrapyramidal symptoms, dizziness, ↑ prolactin, hepatotoxicity, weight gain.</td>
<td>Short-term use (1–4 months) only for severe aggression associated with ADHD.</td>
</tr>
<tr>
<td>Olanzapine</td>
<td>2.5–5 mg bd may titrate every 3–4 days as tolerated to response (usual range 7.5–15 mg/d)</td>
<td>Sedation, weight gain, restlessness, diabetes, hyperlipidaemia.</td>
<td></td>
</tr>
<tr>
<td>Ziprasidone</td>
<td>10–20 mg bd may titrate every 3–4 days as tolerated to response (usual range 40–120 mg/d)</td>
<td>Nausea, restlessness, insomnia, QT prolongation.</td>
<td></td>
</tr>
<tr>
<td>Haloperidol</td>
<td>0.5–1 mg bd may titrate every 3–4 days as tolerated to response (usual range 0.5–5 mg/d)</td>
<td>Extrapyramidal symptoms, dizziness, ↑ prolactin, sedation.</td>
<td></td>
</tr>
</tbody>
</table>
Bupropion blocks the reuptake of noradrenaline and dopamine and has more stimulant properties than the TCAs.\textsuperscript{22} It has been found to have a modest efficacy in decreasing hyperactivity and aggressive behaviour.\textsuperscript{22} It can cause motor tics and lower the seizure threshold.\textsuperscript{22}

- **Clonidine**
  Clonidine an alpha-2-adrenergic agonist has been found to be effective in reducing symptoms in ADHD but is not as effective as stimulants.\textsuperscript{22} It may be useful in over-aroused, easily frustrated, highly active or aggressive individuals.\textsuperscript{22} It has been used in patients with ADHD who also have tics or Tourette syndrome.\textsuperscript{22} It has been used alongside methylphenidate to reduce the incidence of tics.\textsuperscript{10} Side effects include sedation, depression, bradycardia, headache and hypotension.\textsuperscript{22} When discontinuing treatment, clonidine should be withdrawn slowly (0.05mg reductions every three days) to prevent rebound hypertension or behavioural dyscontrol.\textsuperscript{9}

- **Antipsychotics**
  Antipsychotic medications such as risperidone, olanzepine, ziprasidone and haloperidol are not recommended for use in children but may have a place in patients with ADHD who are severely aggressive. Treatment is usually only recommended for a short period of time (one to four months).\textsuperscript{8} Risperidone is registered for disruptive behaviour disorders in children five years and older with sub-average intellectual functioning or mental retardation where destructive behaviour is prominent.\textsuperscript{21}

**Evidence-based recommendations**

The evidence-based recommendations listed below are based on the following guidelines:

- American Academy of Pediatrics, Committee on Quality Improvement and Subcommittee on Attention-Deficit/Hyperactivity Disorder. Diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder.\textsuperscript{9}
- American Academy of Pediatrics. Clinical Practice Guideline: Treatment of the School-Aged Child With Attention Deficit/Hyperactivity Disorder.\textsuperscript{18}
- AACAP Work Group on Quality Issues. Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder.\textsuperscript{1}
- NICE clinical guideline 72. Attention deficit hyperactivity disorder. Diagnosis and management of ADHD in children, young people and adults.\textsuperscript{2}

- **Recommendation one:** Screening for ADHD should be part of every patient’s Mental Health Assessment.\textsuperscript{1}
- **Recommendation two:** Evaluation of the preschooler, child or adolescent for ADHD should consist of clinical interviews with the patient and parent, obtaining information about the patient’s school or day care functioning, evaluation for co-morbid psychiatric disorders, and review of the patient’s medical, social, and family histories.\textsuperscript{1}
- **Recommendation three:** If the patient’s medical history is unremarkable, laboratory or neurological testing is not indicated.\textsuperscript{1}
- **Recommendation four:** Psychological and neuropsychological tests are not mandatory for the diagnosis for ADHD, but should be performed if the patient’s history suggests low general cognitive ability or low achievement in language or mathematics relative to the patient’s intellectual ability.\textsuperscript{1,9}
- **Recommendation five:** The patient with ADHD must be evaluated for the presence of co-morbid psychiatric disorders.\textsuperscript{1,9}
- **Recommendation six:** A well-thought out and comprehensive treatment plan should be developed for the patient.\textsuperscript{1,18}
- **Recommendation seven:** The initial treatment of ADHD should be with a trial with an agent indicated for the treatment of ADHD i.e. methylphenidate or atomoxetine.
- **Recommendation eight:** If none of the above agents result in satisfactory treatment of the patient with ADHD, the diagnosis should be carefully reviewed and then behaviour therapy and/or other agents used (but not licensed) for ADHD should be considered.\textsuperscript{1,18}
- **Recommendation nine:** During pharmacological treatment for ADHD, the patient should be monitored for treatment-emergent side effects.\textsuperscript{1,18}
- **Recommendation ten:** If the patient with ADHD responds well to pharmacological treatment alone by showing full remission of symptoms and normative functioning it is not mandatory that behaviour therapy be added to the regimen.\textsuperscript{1}
- **Recommendation eleven:** If a patient with ADHD has a less than optimal response to medication, has a co-morbid disorder, or experiences stressors in family life, then psychosocial treatment in conjunction with medication is often beneficial.\textsuperscript{1}
- **Recommendation twelve:** Patients should be assessed periodically to determine whether there is a continued need for treatment or if symptoms have remitted. Treatment of ADHD should continue as long as symptoms remain present and cause impairment.\textsuperscript{1}
- **Recommendation thirteen:** Patients treated with medication for ADHD should have their weight and height monitored throughout treatment.\textsuperscript{1}
Factors to consider

- No single treatment is the answer for every patient – a number of factors are involved in determining the best treatment for the individual.10
- Drug treatment is not recommended as first line in children under the age of five.2,10
- If using methylphenidate the choice of preparation needs to be considered: modified-release preparations are convenient due to their pharmacokinetic profile, improving adherence, reducing stigma (drug does not need to be taken at school); and immediate-release preparations are preferred if more flexible dosing is required or during initial titration to determine correct dosing levels.
- Co-morbidities must be treated1,2,18
- It is recommended by manufacturers that drug treatment is suspended every one to two years so that the child’s condition can be reassessed.10
- Patients not continuing with therapy need to be given appropriate withdrawal strategies.10

Adult ADHD

Drug treatment for adults with ADHD should always be part of a comprehensive treatment programme that takes into account psychological, behavioural and educational or occupational needs.3 Behavioural therapy usually involves life coaching which can assist patients in restructuring dysfunctional life patterns.11 Pharmacological treatment includes both stimulant i.e. methylphenidate and non-stimulant i.e. atomoxetine medications. These medications can help patients focus and organise their lives.11 Both Ritalin® and Strattera® have adult registration in South Africa.3 NICE guidelines recommend that once a decision has been made to start drug treatment in adults then methylphenidate should normally be tried first.2 Blood pressure and heart rate should be closely monitored when initiating stimulant therapy as cardiovascular effects are more of a concern in children than in adults, and may be used when there is co-morbid anxiety.10

Conclusion

ADHD should be treated as a chronic illness that requires ongoing management, monitoring and treatment to prevent relapse. Treatment may need to be continued through adolescence and into adulthood. Pharmacological therapy should form part of a comprehensive treatment plan which should include psychological, educational and social measures that is implemented on an individual patient basis after consultation with patients, parents and teachers.

References

7. UpToDate Attention deficit hyperactivity disorder in children and adolescents: Epidemiology and pathogenesis. Author Kevin R Krull, Section Editor Marilyn Augustyn, Deputy Editor Mary M Torchia. Last updated 4 January 2010.
12. UpToDate Attention Deficit Hyperactivity Disorder in children and adolescents: Clinical features and evaluation. Author Kevin R Krull Section Editor Marilyn Augustyn Deputy Editor Mary M Torchia. Last updated 25 March 2009.
13. Attention Deficit Hyperactivity Disorder South Africa (ADHDSA) website www.adhdsa.co.za
16. UpToDate Overview of the treatment and prognosis of Attention Deficit Hyperactivity Disorder in children and adolescents. Author Kevin R Krull Section Editor Marilyn Augustyn Deputy Editor Mary M Torchia. Last updated 28 May 2009.
18. MIMS Volume 50 Number 2 February 2010.
19. UpToDate Attention deficit hyperactivity disorder in children and adolescents: Pharmacotherapy. Author Kevin R Krull, Section Editor Marilyn Augustyn, Deputy Editor Mary M Torchia. Last updated 30 September 2009.
21. ‘When ADHD grows up’ an interview with Dr David Benn in ‘What’s New Doc’ 09_02/03 2010 p28-30.